CNS-targeted glucocorticoid reduces pathology in mouse model of amyotrophic lateral sclerosis

• Published in: Acta neuropathologica communications Vol. 2; no. 1; p. 66
• Main Authors: Evans, Matthew C, Gaillard, Pieter J, de Boer, Marco, Appeldoorn, Chantal, Dorland, Rick, Sibson, Nicola R, Turner, Martin R, Anthony, Daniel C, Stolp, Helen B
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 13-06-2014; BioMed Central
• Subjects: Amyotrophic Lateral Sclerosis - drug therapy; Amyotrophic Lateral Sclerosis - genetics; Animals; Area Under Curve; Body Weight - drug effects; Cell Survival - drug effects; Central Nervous System - drug effects; Central Nervous System - physiology; Comparative analysis; Disease Models, Animal; Drug Delivery Systems; Glucocorticoids - administration & dosage; Glucocorticoids - pharmacology; Glutathione - administration & dosage; Glutathione - pharmacology; Humans; Methylprednisolone - administration & dosage; Methylprednisolone - pharmacology; Mice; Mice, Transgenic; Motor Activity - drug effects; Motor Neurons - drug effects; Motor Neurons - pathology; Neuroglia - drug effects; Neuroglia - physiology; Neurons; Physiological aspects; Political aspects; Polyethylene Glycols - administration & dosage; Polyethylene Glycols - pharmacology; Steroids; Superoxide Dismutase - genetics; Time Factors; Vacuoles - drug effects; Vacuoles - pathology
• ISSN: 2051-5960; 2051-5960
• DOI: 10.1186/2051-5960-2-66

Hallmarks of CNS inflammation, including microglial and astrocyte activation, are prominent features in post-mortem tissue from amyotrophic lateral sclerosis (ALS) patients and in mice overexpressing mutant superoxide dismutase-1 (SOD1G93A). Administration of non-targeted glucocorticoids does not significantly alter disease progression, but this may reflect poor CNS delivery. Here, we sought to discover whether CNS-targeted, liposomal encapsulated glucocorticoid would inhibit the CNS inflammatory response and reduce motor neuron loss. SOD1G93A mice were treated with saline, free methylprednisolone (MP, 10 mg/kg/week) or glutathione PEGylated liposomal MP (2B3-201, 10 mg/kg/week) and compared to saline treated wild-type animals. Animals were treated weekly with intravenous injections for 9 weeks from 60 days of age. Weights and motor performance were monitored during this period. At the end of the experimental period (116 days) mice were imaged using T2-weighted MRI for brainstem pathology; brain and spinal cord tissue were then collected for histological analysis.
All SOD1G93A groups showed a significant decrease in motor performance, compared to baseline, from ~100 days. SOD1G93A animals showed a significant increase in signal intensity on T2 weighted MR images, which may reflect the combination of neuronal vacuolation and glial activation in these motor nuclei. Treatment with 2B3-201, but not free MP, significantly reduced T2 hyperintensity observed in SOD1G93A mice. Compared to saline-treated and free-MP-treated SOD1G93A mice, those animals given 2B3-201 displayed significantly improved histopathological outcomes in brainstem motor nuclei, which included reduced gliosis and neuronal loss.
In contrast to previous reports that employed free steroid preparations, CNS-targeted anti-inflammatory agent 2B3-201 (liposomal methylprednisolone) has therapeutic potential, reducing brainstem pathology in the SOD1G93A mouse model of ALS. 2B3-201 reduced neuronal loss and vacuolation in brainstem nuclei, and reduced activation preferentially in astrocytes compared with microglia. These data also suggest that other previously ineffective therapies could be of therapeutic value if delivered specifically to the CNS.